BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8417011)

  • 1. 6-[18F]fluoro-L-dopa metabolism in living human brain: a comparison of six analytical methods.
    Hoshi H; Kuwabara H; Léger G; Cumming P; Guttman M; Gjedde A
    J Cereb Blood Flow Metab; 1993 Jan; 13(1):57-69. PubMed ID: 8417011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease.
    Kuwabara H; Cumming P; Yasuhara Y; Léger GC; Guttman M; Diksic M; Evans AC; Gjedde A
    J Nucl Med; 1995 Jul; 36(7):1226-31. PubMed ID: 7790948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human striatal L-dopa decarboxylase activity estimated in vivo using 6-[18F]fluoro-dopa and positron emission tomography: error analysis and application to normal subjects.
    Kuwabara H; Cumming P; Reith J; Léger G; Diksic M; Evans AC; Gjedde A
    J Cereb Blood Flow Metab; 1993 Jan; 13(1):43-56. PubMed ID: 8417009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
    Kumakura Y; Gjedde A; Danielsen EH; Christensen S; Cumming P
    J Cereb Blood Flow Metab; 2006 Mar; 26(3):358-70. PubMed ID: 16079784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of striatal 18F-dopa uptake in adult-onset dystonia-parkinsonism, Parkinson's disease, and dopa-responsive dystonia.
    Turjanski N; Bhatia K; Burn DJ; Sawle GV; Marsden CD; Brooks DJ
    Neurology; 1993 Aug; 43(8):1563-8. PubMed ID: 8351012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Brooks DJ; Ibanez V; Sawle GV; Quinn N; Lees AJ; Mathias CJ; Bannister R; Marsden CD; Frackowiak RS
    Ann Neurol; 1990 Oct; 28(4):547-55. PubMed ID: 2132742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease.
    Antonini A; Vontobel P; Psylla M; Günther I; Maguire PR; Missimer J; Leenders KL
    Arch Neurol; 1995 Dec; 52(12):1183-90. PubMed ID: 7492293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.
    Ishikawa T; Dhawan V; Chaly T; Margouleff C; Robeson W; Dahl JR; Mandel F; Spetsieris P; Eidelberg D
    J Nucl Med; 1996 Feb; 37(2):216-22. PubMed ID: 8667047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of partial volume correction on estimates of the influx and cerebral metabolism of 6-[(18)F]fluoro-L-dopa studied with PET in normal control and Parkinson's disease subjects.
    Rousset OG; Deep P; Kuwabara H; Evans AC; Gjedde AH; Cumming P
    Synapse; 2000 Aug; 37(2):81-9. PubMed ID: 10881028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
    Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
    Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa effect on [18F]fluorodopa influx to brain: normal volunteers and patients with Parkinson's disease.
    Kumakura Y; Danielsen EH; Reilhac A; Gjedde A; Cumming P
    Acta Neurol Scand; 2004 Sep; 110(3):188-95. PubMed ID: 15285777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease.
    Dietz M; Harder S; Graff J; Künig G; Vontobel P; Leenders KL; Baas H
    Clin Pharmacol Ther; 2001 Jul; 70(1):33-41. PubMed ID: 11452242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopa-responsive dystonia: [18F]dopa positron emission tomography.
    Sawle GV; Leenders KL; Brooks DJ; Harwood G; Lees AJ; Frackowiak RS; Marsden CD
    Ann Neurol; 1991 Jul; 30(1):24-30. PubMed ID: 1681782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
    Morrish PK; Rakshi JS; Bailey DL; Sawle GV; Brooks DJ
    J Neurol Neurosurg Psychiatry; 1998 Mar; 64(3):314-9. PubMed ID: 9527140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relation of putamen and caudate nucleus 18F-Dopa uptake to motor and cognitive performances in Parkinson's disease.
    Broussolle E; Dentresangle C; Landais P; Garcia-Larrea L; Pollak P; Croisile B; Hibert O; Bonnefoi F; Galy G; Froment JC; Comar D
    J Neurol Sci; 1999 Jul; 166(2):141-51. PubMed ID: 10475108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease.
    Antonini A; Leenders KL; Vontobel P; Maguire RP; Missimer J; Psylla M; Günther I
    Brain; 1997 Dec; 120 ( Pt 12)():2187-95. PubMed ID: 9448574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.
    Leenders KL; Salmon EP; Tyrrell P; Perani D; Brooks DJ; Sager H; Jones T; Marsden CD; Frackowiak RS
    Arch Neurol; 1990 Dec; 47(12):1290-8. PubMed ID: 2123623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study.
    Nurmi E; Ruottinen HM; Bergman J; Haaparanta M; Solin O; Sonninen P; Rinne JO
    Mov Disord; 2001 Jul; 16(4):608-15. PubMed ID: 11481683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-[18F]fluorodopa metabolism in patients with hemiparkinsonism studied by positron emission tomography.
    Nagasawa H; Saito H; Kogure K; Hatazawa J; Itoh M; Fujiwara T; Watanuki S; Seo S; Iwata R; Ido T
    J Neurol Sci; 1993 Apr; 115(2):136-43. PubMed ID: 8482975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders.
    Stormezand GN; Chaves LT; Vállez García D; Doorduin J; De Jong BM; Leenders KL; Kremer BPH; Dierckx RAJO
    Neuroimage Clin; 2020; 25():102161. PubMed ID: 31981888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.